is the major cause of infectious blindness and represents the most common bacterial sexually transmitted infection worldwide. Considering the potential side effects of antibiotic therapy and increasing threat of antibiotic resistance, alternative therapeutic strategies are needed. Previous studies showed that water filtered infrared A alone (wIRA) or in combination with visible light (wIRA/VIS) reduced infectivity. Furthermore, wIRA/VIS irradiation led to secretion of pro-inflammatory cytokines similar to that observed upon infection. We confirmed the results of previous studies, namely that cytokine secretion (IL-6, IL-8, and RANTES/CCL5) upon wIRA/VIS treatment, and the subsequent reduction of chlamydial infectivity, are independent of the addition of cycloheximide, a host protein synthesis inhibitor. Reproducible cytokine release upon irradiation indicated that cytokines might be involved in the anti-chlamydial mechanism of wIRA/VIS. This hypothesis was tested by inhibiting IL-6, IL-8, and RANTES secretion in or mock-infected cells by gene silencing or pharmaceutical inhibition. Celastrol, a substance derived from , used in traditional Chinese medicine and known for anti-cancer and anti-inflammatory effects, was used for IL-6 and IL-8 inhibition, while Maraviroc, a competitive CCR5 antagonist and anti-HIV drug, served as a RANTES/CCL5 inhibitor. HeLa cell cytotoxicity and impact on chlamydial morphology, size and inclusion number was evaluated upon increasing inhibitor concentration, and concentrations of 0.1 and 1 μM Celastrol and 10 and 20 μM Maraviroc were subsequently selected for irradiation experiments. Celastrol at any concentration reduced chlamydial infectivity, an effect only observed for 20 μM Maraviroc. Triple dose irradiation (24, 36, 40 hpi) significantly reduced chlamydial infectivity regardless of IL-6, IL-8, or RANTES/CCL5 gene silencing, Celastrol or Maraviroc treatment. Neither gene silencing nor pharmaceutical cytokine inhibition provoked the chlamydial stress response. The anti-chlamydial effect of wIRA/VIS is independent of cytokine inhibition under all conditions evaluated. Thus, factors other than host cell cytokines must be involved in the working mechanism of wIRA/VIS. This study gives a first insight into the working mechanism of wIRA/VIS in relation to an integral component of the host immune system and supports the potential of wIRA/VIS as a promising new tool for treatment in trachoma.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262300 | PMC |
http://dx.doi.org/10.3389/fmicb.2018.02757 | DOI Listing |
Alzheimers Dement
December 2024
Institute of Public and Preventative Health, Augusta, GA, USA.
Background: Physiological changes, including metabolic and cellular aging, as well as increased inflammation, occur in people living with dementia (PWD). While there is existing evidence in other populations suggesting that exercise may improve physiological outcomes, their impact in PWD remains unclear. This randomized controlled trial (RCT) aimed to assess the effects of exercise on serum levels of metabolic aging, cellular aging, and inflammatory blood biomarkers relative to usual care alone in PWD.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
UNICAMP, Campinas, Brazil; Sao Leopoldo Mandic Araras School of Medicine, Araras, Brazil; USP - University of Sao Paulo, Ribeirao Preto, Brazil.
Background: Neuroinflammation can be considered a risk factor for the onset or progression of Alzheimer's dementia. In a neuroinflammatory process, the death of neurons may accelerate, favoring the progression of Alzheimer's disease. The release of pro-inflammatory proteins can, for example, cause synaptic dysfunction and impede neurogenesis.
View Article and Find Full Text PDFBackground: People living with dementia (PWD) have upregulated inflammatory pathways, exaggerated metabolic aging, and cellular aging. They also have declines in physical function and heightened fall-risk. Understanding the physiologic factors that influence physical decline and fall-risk in PWD is vital to assess and prevent adverse health outcomes, such as future falls.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
The Pennsylvania State University, University Park, PA, USA.
Background: Inflammation is a risk factor for cognitive decline, mild cognitive impairment (MCI), and Alzheimer's disease (AD). While past research in laboratory settings suggests that inflammation relates to cognitive decline and MCI status, more research is needed to examine such associations in everyday life. The present work addressed this gap by examining MCI and gender stratified links between circulating inflammatory biomarkers and self-reported prospective memory (PM; i.
View Article and Find Full Text PDFBackground: Patients with rapid progressive Alzheimer disease and related dementias (rpAD/ADRD) develop dementia within 1 year or incapacitation within 2 years of symptom onset. We previously showed that selected CSF biomarkers of neuronal injury (NfL, VILIP-1), AD neuropathology (p-tau181), and neuroinflammation (GFAP, MCP-1, sTREM2) measured at presentation associated with etiologic diagnoses and reliably differentiated patients with treatment-responsive causes of rapid progressive dementia. However, no differences were identified between CSF biomarkers in patients with rapid and typical progressive forms of AD/ADRD, leaving key questions unanswered concerning the mechanisms that drive rpAD/ADRD.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!